NGEF: A Potential Drug Target and Biomarker for Neurological Disorders

Target Name: NGEF

NCBI ID: G25791

NGEF

NGEF: A Potential Drug Target and Biomarker for Neurological Disorders

NGEF (NGEF_HUMAN) is a protein that is expressed in various tissues of the human body. It is a key regulator of neural growth and development, and is involved in the formation of neural circuits in the brain. Despite its importance, little is known about NGEF. In this article, we will explore the potential of NGEF as a drug target and its potential as a biomarker for various neurological disorders.

NGEF is a transmembrane protein that is expressed in various tissues of the human body, including the brain, heart, and kidneys. It is a key regulator of neural growth and development, and is involved in the formation of neural circuits in the brain. NGEF is composed of an extracellular domain, a transmembrane domain, and an intracellular domain. The extracellular domain of NGEF consists of a N-terminus that is involved in cell adhesion, and a C-terminus that is involved in protein-protein interactions. The transmembrane domain of NGEF consists of a series of transmembrane伪 helical structure, which are thought to play a key role in NGEF's stability and localization to the plasma membrane. The intracellular domain of NGEF consists of a series of cytoplasmic tail, which are involved in NGEF's internal signaling pathway.

One of the most promising aspects of NGEF is its potential as a drug target. NGEF has been shown to play a role in a variety of neurological disorders, including cancer, neurodegenerative diseases, and autoimmune diseases. NGEF has also been shown to interact with a variety of signaling pathways, including TGF-β, NF-kappa-B, and PI3K/AKT. Therefore, NGEF may be a promising target for small molecule inhibitors, antibodies, or other therapeutic agents that can modulate NGEF activity and improve therapeutic outcomes.

Another potential use of NGEF is as a biomarker for various neurological disorders. NGEF is highly expressed in a variety of neurological tissues, including brain, heart, and kidney. Therefore, NGEF may be a useful biomarker for assessing the severity and progression of neurological disorders. . For example, high levels of NGEF expression may indicate the presence of neurodegenerative diseases, while decreased levels of NGEF expression may indicate the presence of cancer or other neurological disorders. Additionally, NGEF may be a useful biomarker for tracking the efficacy of therapeutic agents in neurological disorders, as changes in NGEF expression levels may reflect the effectiveness of different treatment options.

In conclusion, NGEF is a protein that is expressed in various tissues of the human body, and has been shown to play a key role in the formation of neural circuits in the brain. Despite its importance, little is known about NGEF. However, its potential as a drug target and biomarker for various neurological disorders makes it an exciting area of 鈥嬧?媟esearch. Further studies are needed to fully understand the role of NGEF in neural growth and development, and to develop effective therapeutic agents that can modulate NGEF activity.

Protein Name: Neuronal Guanine Nucleotide Exchange Factor

Functions: Acts as a guanine nucleotide exchange factor (GEF) which differentially activates the GTPases RHOA, RAC1 and CDC42. Plays a role in axon guidance regulating ephrin-induced growth cone collapse and dendritic spine morphogenesis. Upon activation by ephrin through EPHA4, the GEF activity switches toward RHOA resulting in its activation. Activated RHOA promotes cone retraction at the expense of RAC1- and CDC42-stimulated growth cone extension (By similarity)

The "NGEF Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NGEF comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets